
Trajenta 5 in Kenya
KSh 5,000.00
Trajenta 5 contains Linagliptin (5mg), a prescription medication for type 2 diabetes mellitus. It works by:
- Inhibiting DPP-4 Enzymes: Increases incretin hormones (GLP-1, GIP), stimulating insulin release and reducing glucagon.
- Lowering Blood Sugar: Improves glycemic control with minimal hypoglycemia risk.
- Preserving Beta-Cell Function: Slows pancreatic cell deterioration.
Approved by the Kenya Pharmacy and Poisons Board (PPB), Trajenta is used as monotherapy or combination therapy (e.g., with metformin, SGLT2 inhibitors).
Add to cart
Buy Now
Product Description
Product Overview
Trajenta 5 contains Linagliptin (5mg), a prescription medication for type 2 diabetes mellitus. It works by:
- Inhibiting DPP-4 Enzymes: Increases incretin hormones (GLP-1, GIP), stimulating insulin release and reducing glucagon.
- Lowering Blood Sugar: Improves glycemic control with minimal hypoglycemia risk.
- Preserving Beta-Cell Function: Slows pancreatic cell deterioration.
Approved by the Kenya Pharmacy and Poisons Board (PPB), Trajenta is used as monotherapy or combination therapy (e.g., with metformin, SGLT2 inhibitors).
Composition
Each tablet contains:
- Active Ingredient: Linagliptin (5mg).
- Inactive Ingredients: Microcrystalline cellulose, lactose monohydrate, magnesium stearate, film-coating agents.
Key Benefits:
- Once-Daily Dosing: Convenient adherence.
- Renal Safety: No dose adjustment needed for kidney impairment.
- Weight-Neutral: No weight gain vs. sulfonylureas/insulin.
How to Use
Dosage & Administration:
- Standard Dose: 5mg once daily, taken orally with or without food.
- Combination Therapy:
- With Metformin: 5mg daily (add-on if metformin alone fails).
- With SGLT2 Inhibitors (e.g., empagliflozin): 5mg daily.
- Special Populations:
- Renal/Hepatic Impairment: No dose adjustment (unlike other DPP-4 inhibitors).
- Elderly: Same dose (monitor for side effects).
Critical Precautions:
- Prescription-Only: Requires endocrinologist/physician approval.
- Avoid in:
- Type 1 diabetes or diabetic ketoacidosis (DKA).
- History of pancreatitis.
- Severe hypersensitivity to linagliptin.
- Monitoring:
- HbA1c: Every 3 months.
- Pancreatic/Liver Enzymes: Baseline and periodically.
Side Effects
Trajenta 5 is generally well-tolerated but may cause:
- Common:
- Nasopharyngitis, headache.
- Hypoglycemia (only when combined with sulfonylureas/insulin).
- Serious (Seek Immediate Help):
- Pancreatitis: Severe abdominal pain, vomiting (discontinue use).
- Severe Joint Pain: May require hospitalization.
- Hypersensitivity: Rash, angioedema (swelling of face/throat).
- Bullous Pemphigoid: Skin blistering (rare).
Black Box Warning:
- Pancreatitis: Discontinue if suspected; fatal cases reported.
Frequently Asked Questions (FAQs)
Q1: Where can I buy Trajenta 5 in Kenya?
A: Available at major pharmacies (Goodlife, Medplus, Lifestores) and diabetes clinics (Kenya Diabetes Management Center). Requires a prescription. Online via MyDawa (with prescription upload).
Q2: What is the price of Trajenta 5 in Kenya?
A: KES 2,500–3,500 for 30 tablets. Generic linagliptin (e.g., Lintra) costs KES 1,800–2,200.
Q3: Is Trajenta covered by NHIF?
A: Partially covered for registered diabetes patients under the National Diabetes Program. Requires pre-authorization.
Q4: How does Trajenta compare to Januvia (sitagliptin)?
A:
|
Feature
|
Trajenta (Linagliptin)
|
Januvia (Sitagliptin)
|
|---|---|---|
| Renal Dosing | No adjustment needed | Requires adjustment |
| Cost (Kenya) | KES 2,500–3,500 | KES 3,000–4,000 |
| Half-Life | >100 hours | 8–14 hours |
Q5: Can I use Trajenta if I have kidney disease?
A: Yes. Unlike sitagliptin/saxagliptin, no dose adjustment is needed for any stage of CKD.
Q6: Are there alternatives?
A: Yes:
- Other DPP-4 Inhibitors: Sitagliptin (Januvia), Saxagliptin (Onglyza).
- SGLT2 Inhibitors: Empagliflozin (Jardiance), Dapagliflozin (Forxiga).
- GLP-1 Agonists: Liraglutide (Victoza), Semaglutide (Ozempic).
Q7: Does Trajenta cause weight gain?
A: No. It is weight-neutral, unlike sulfonylureas, insulin, or TZDs.
Q8: How long until it works?
A: HbA1c reduction seen in 3–6 months.
Conclusion
Trajenta 5 (Linagliptin) is a preferred DPP-4 inhibitor in Kenya for type 2 diabetes, offering renal safety and once-daily convenience. Its lack of dose adjustment for kidney disease makes it ideal for patients with comorbid CKD. While more expensive than older drugs (e.g., sulfonylureas), its safety profile justifies use in high-risk groups.
For Safe Use:
- Never self-prescribe – endocrinologist oversight is essential.
- Combine with Lifestyle: Diet/exercise remain foundational.
- Monitor for Pancreatitis: Report severe abdominal pain immediately.
- Choose Generics: Linagliptin offers identical efficacy at lower cost.
- Leverage NHIF: Apply for coverage to reduce financial burden.
Optimize your diabetes management—consult an endocrinologist to see if Trajenta 5 is right for you!
Be the first to review “Trajenta 5 in Kenya” Cancel reply



Reviews
There are no reviews yet.